Valuence Merger I in an 8-K said shareholders approved an initial two-month extension on the SPAC’s completion deadline to Aug. 3, with the option at the board’s discretion to extend an additional 19 months, which would be March 2026.
The SPAC lost more than two-thirds of its shares outstanding to redemptions in connection with the last extension vote a year ago. Another 4,343,316 Class A shares were redeemed on the latest extension vote. That leaves the SPAC with a trust balance of $21.5 million.
Valuence I completed a $200 million IPO in March 2022. Since then, it has focused on life sciences targets based in Asia, though excluding China, Hong Kong and Macau. The SPAC has yet to announce a deal. Read more.
